Cutler Group’s Kalaris Therapeutics KLRS Stock Holding History

Cutler Group’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-30	Closed	-$2K	–	5635
2020 Q3	$2K	Buy	+30	New	+$20.5K	﹤0.01%	4166

Other funds holding KLRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Cutler Group's KLRS Position: Q4 2022 in Review

Cutler Group sold out of Kalaris Therapeutics (KLRS) in Q4 2022, closing a stake of 78 shares — an estimated $14K sold.

Cutler Group first reported a position in KLRS in Q3 2020 and held it in 3 quarters. The position peaked at $14K in Q3 2022. 85 funds tracked by Wall St. Rank hold KLRS as of Q4 2022.

Cutler Group reported no remaining Kalaris Therapeutics position as of Q4 2022 after selling out during the quarter.
Cutler Group sold 78 Kalaris Therapeutics shares in Q4 2022, an estimated $14K.
Cutler Group first reported a position in Kalaris Therapeutics in Q3 2020 and held it in 3 quarters.
Cutler Group's Kalaris Therapeutics position peaked at $14K in Q3 2022.
85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2022.

Based on Cutler Group's 13F filing for Q4 2022, filed 7 Feb 2023.